BACKGROUND: Epidemiological evidence shows a strong relationship between decreased serum magnesium levels (DSML) and insulin resistance. As nonalcoholic steatohepatitis (NASH) seems to be related to insulin resistance, the aim of this study was to determine the potential relationship between DSML and NASH in obese subjects. METHODS: We compared obese individuals with the diagnosis of diabetes, insulin-resistance, and non-insulin resistance to a control group of non-obese, non-insulin-resistant subjects. Participants were required to have negative viral markers and negligible alcohol intake. Other liver diseases and well-known causes for decreasing of magnesium were exclusion criteria. A liver biopsy was performed in subjects with aspartate aminotransferase (AST) and alanine aminotransferease (ALT) levels > or =40 IU/mL. RESULTS: Of the 60 obese subjects, 20 were non-insulin resistant, 20 were insulin resistant, and 20 were type 2 diabetics. Twenty subjects were in the control group. Eleven (33.3%) diabetics, 14 (42.4%) insulin-resistant subjects, and 8 (24.2%) non-insulin-resistant subjects underwent liver biopsies. Diagnosis of NASH was established in 29 (36.2%) individuals. Subjects with the diagnosis of NASH exhibited lower serum magnesium levels of 1.7 +/- 0.2 mg/dL (0.70 +/- 0.08 mmol/L), and those with fibrosis showed the lowest serum magnesium concentration at 1.5 +/- 0.3 mg/dL (0.62 +/- 0.12 mmol/L). Multiple regression analysis adjusted by age showed that low serum magnesium concentration was independently related to a high HOMA-IR index (OR 7.6, CI 95% 2.1-11.2; p <0.0001) and that a high HOMA-IR index was related to NASH (OR 6.5, CI 95% 1.5-8.8; p <0.01). After adjusting for age and a high HOMA-IR index, hypomagnesemia remained independently related to NASH (OR 1.4, CI 95% 1.1-5.4; p <0.05). CONCLUSIONS: The results of this study demonstrate an independent relationship between DSML and NASH.
BACKGROUND: Epidemiological evidence shows a strong relationship between decreased serum magnesium levels (DSML) and insulin resistance. As nonalcoholic steatohepatitis (NASH) seems to be related to insulin resistance, the aim of this study was to determine the potential relationship between DSML and NASH in obese subjects. METHODS: We compared obese individuals with the diagnosis of diabetes, insulin-resistance, and non-insulin resistance to a control group of non-obese, non-insulin-resistant subjects. Participants were required to have negative viral markers and negligible alcohol intake. Other liver diseases and well-known causes for decreasing of magnesium were exclusion criteria. A liver biopsy was performed in subjects with aspartate aminotransferase (AST) and alanine aminotransferease (ALT) levels > or =40 IU/mL. RESULTS: Of the 60 obese subjects, 20 were non-insulin resistant, 20 were insulin resistant, and 20 were type 2 diabetics. Twenty subjects were in the control group. Eleven (33.3%) diabetics, 14 (42.4%) insulin-resistant subjects, and 8 (24.2%) non-insulin-resistant subjects underwent liver biopsies. Diagnosis of NASH was established in 29 (36.2%) individuals. Subjects with the diagnosis of NASH exhibited lower serum magnesium levels of 1.7 +/- 0.2 mg/dL (0.70 +/- 0.08 mmol/L), and those with fibrosis showed the lowest serum magnesium concentration at 1.5 +/- 0.3 mg/dL (0.62 +/- 0.12 mmol/L). Multiple regression analysis adjusted by age showed that low serum magnesium concentration was independently related to a high HOMA-IR index (OR 7.6, CI 95% 2.1-11.2; p <0.0001) and that a high HOMA-IR index was related to NASH (OR 6.5, CI 95% 1.5-8.8; p <0.01). After adjusting for age and a high HOMA-IR index, hypomagnesemia remained independently related to NASH (OR 1.4, CI 95% 1.1-5.4; p <0.05). CONCLUSIONS: The results of this study demonstrate an independent relationship between DSML and NASH.
Authors: Chloe P Lozano; Lynne R Wilkens; Yurii B Shvetsov; Gertraud Maskarinec; Song-Yi Park; John A Shepherd; Carol J Boushey; James R Hebert; Michael D Wirth; Thomas Ernst; Timothy Randolph; Unhee Lim; Johanna W Lampe; Loïc Le Marchand; Meredith A J Hullar Journal: Am J Clin Nutr Date: 2022-05-01 Impact factor: 8.472
Authors: Ahad Eshraghian; Saman Nikeghbalian; Bita Geramizadeh; Seyed Ali Malek-Hosseini Journal: United European Gastroenterol J Date: 2017-04-25 Impact factor: 4.623
Authors: Jorge Simón; Naroa Goikoetxea-Usandizaga; Marina Serrano-Maciá; David Fernández-Ramos; Diego Sáenz de Urturi; Jessica J Gruskos; Pablo Fernández-Tussy; Sofía Lachiondo-Ortega; Irene González-Recio; Rubén Rodríguez-Agudo; Virginia Gutiérrez-de-Juan; Begoña Rodríguez-Iruretagoyena; Marta Varela-Rey; Paula Gimenez-Mascarell; María Mercado-Gomez; Beatriz Gómez-Santos; Carmen Fernandez-Rodriguez; Fernando Lopitz-Otsoa; Maider Bizkarguenaga; Sibylle Dames; Ute Schaeper; Franz Martin; Guadalupe Sabio; Paula Iruzubieta; Javier Crespo; Patricia Aspichueta; Kevan H-Y Chu; Daniela Buccella; César Martín; Teresa Cardoso Delgado; Luis Alfonso Martínez-Cruz; María Luz Martínez-Chantar Journal: J Hepatol Date: 2021-02-09 Impact factor: 25.083
Authors: Majid Karandish; Mahtab Tamimi; Ali Akbar Shayesteh; Mohammad Hosein Haghighizadeh; Mohammad Taha Jalali Journal: J Res Med Sci Date: 2013-07 Impact factor: 1.852